ProShare Advisors’s C4 Therapeutics CCCC Stock Holding History

ProShare Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.9K	Buy	+16,895	New	+$57.8K	﹤0.01%	1804
2025 Q2	–	Sell	-16,223	Closed	-$26K	–	2090
2025 Q1	$26K	Sell	16,223 -4,060	-20%	-$12.1K	﹤0.01%	2016
2024 Q4	$73K	Buy	20,283 +9,204	+83%	+$45.8K	﹤0.01%	2125
2024 Q3	$63.1K	Buy	+11,079	New	+$66.7K	﹤0.01%	1950
2022 Q2	–	Sell	-12,296	Closed	-$299K	–	1835
2022 Q1	$299K	Sell	12,296 -2,989	-20%	-$72.6K	﹤0.01%	1631
2021 Q4	$492K	Buy	15,285 +10,334	+209%	+$409K	﹤0.01%	1456
2021 Q3	$221K	Sell	4,951 -3,983	-45%	-$171K	﹤0.01%	1741
2021 Q2	$338K	Buy	+8,934	New	+$320K	﹤0.01%	1812

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ProShare Advisors's CCCC Position: Q2 2026 in Review

ProShare Advisors opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 16,895 shares worth $78.9K. The stake represents ﹤0.01% of the portfolio and ranks #1804 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in CCCC as recently as Q1 2025.

ProShare Advisors first reported a position in CCCC in Q2 2021 and has held it in 8 quarters since. The position peaked at $492K in Q4 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

ProShare Advisors held 16,895 shares of C4 Therapeutics worth $78.9K as of Q2 2026.
C4 Therapeutics was a new ProShare Advisors position in Q2 2026.
C4 Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1804 holding.
ProShare Advisors first reported a position in C4 Therapeutics in Q2 2021 and has held it in 8 quarters since.
ProShare Advisors's C4 Therapeutics position peaked at $492K in Q4 2021.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.